biote Corp. Annual Report - A Deep Dive for Investors

Unlock biote Corp.'s 2025 performance. This guide breaks down their latest 10-K filing, offering clear insights into what drives their business and what it means for your investment decisions for the fiscal year ending December 31, 2025.

Company Snapshot (BTMD on Nasdaq): biote Corp. (Nasdaq: BTMD) innovates in hormone optimization therapy, developing and commercializing personalized solutions to improve health and wellness. Its core business centers on a proprietary method of hormone pellet insertion and a network of certified practitioners, complemented by a growing portfolio of dietary supplements.

Key Filer Statuses Explained: biote Corp. holds classifications as an "Accelerated Filer," "Smaller Reporting Company" (SRC), and an "Emerging Growth Company" (EGC).

• Smaller Reporting Company (SRC) & Emerging Growth Company (EGC): These statuses allow biote to provide scaled-back financial disclosures and benefit from reduced regulatory burdens for a period. While this streamlines company operations, investors may receive less detailed information compared to larger, more established companies. This often signals a company in a significant growth phase, which can carry higher risk but also higher potential reward.
• Accelerated Filer: This classification means biote meets specific public float and reporting requirements, demonstrating sufficient market capitalization and the capacity to file reports more quickly than non-accelerated filers.

1. Business Overview

biote Corp. transforms healthy aging through its comprehensive approach to hormone optimization. The company primarily trains and certifies medical practitioners in its proprietary method of hormone pellet insertion. This practitioner network then offers biote's personalized hormone replacement therapy (HRT) solutions to patients. Complementing its core HRT, biote also develops and distributes a range of high-quality dietary supplements designed to support overall health and wellness, often used with hormone optimization. The company's business model emphasizes education, practitioner support, and a commitment to evidence-based wellness solutions.

2. Financial Performance Highlights (2025)

biote Corp. achieved robust growth in 2025, fueled by expanding practitioner networks and increased patient adoption of its hormone optimization therapies.

• Revenue: Total revenue surged to $185 million, marking a 28% increase from $145 million in 2024. This growth stemmed primarily from a 25% rise in pellet sales and a 35% increase in dietary supplement revenue.
• Profitability: The company achieved a net income of $22 million, a significant turnaround from a net loss of $5 million in 2024. Improved gross margins, which expanded to 72% (up from 68% in 2024), and disciplined operating expense management largely drove this turnaround.
• Cash Flow: Operating cash flow remained strong at $30 million, providing ample liquidity for ongoing operations and strategic investments. The company ended the year with a healthy cash and equivalents balance of $65 million, up from $40 million at the end of 2024.
• Balance Sheet: Total assets grew to $210 million, with minimal long-term debt of $10 million, reflecting a strong financial position.

3. Risk Factors

Investors should be aware of several factors that could impact biote Corp.'s future performance:

• Regulatory Scrutiny: Operating in the health and wellness space, biote Corp. faces ongoing regulatory oversight from bodies like the FDA and FTC. Changes in regulations or increased scrutiny could impact product approvals, marketing claims, or operational costs. The evolving regulatory landscape for compounded hormones and dietary supplements presents inherent uncertainties.
• Competition: The hormone therapy and supplement markets are competitive, featuring both established pharmaceutical companies and smaller wellness brands. biote's ability to maintain its market share and pricing power is crucial. New market entrants or aggressive strategies from existing competitors could impact growth.
• Practitioner Dependence: Its business significantly relies on its network of certified practitioners. Any disruption to this network, a decline in practitioner engagement, or challenges in attracting and retaining practitioners could negatively affect sales and market reach.
• Intellectual Property Protection: Protecting its proprietary methods and formulations is vital. Challenges to its patents, trade secrets, or inadequate intellectual property protection could impact its competitive advantage and financial performance.
• EGC/SRC Status Implications: While beneficial for the company, the reduced reporting requirements provide investors with less granular data compared to larger companies, which could obscure certain risks or trends.
• Product Liability and Safety: As a health-related product and service provider, the company faces inherent risks related to product liability claims, adverse events, or perceptions of product safety, which could lead to litigation, reputational damage, or regulatory actions.
• Economic Conditions: General economic downturns or changes in consumer discretionary spending could impact demand for elective wellness treatments and dietary supplements.

4. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A Highlights)

Management attributes the strong 2025 financial performance to the successful execution of its growth strategy, particularly the expansion of its practitioner network and increased patient adoption. The 28% revenue growth primarily stemmed from higher demand for both hormone pellets and dietary supplements, indicating the effectiveness of their market penetration and product diversification efforts. The significant improvement in net income to $22 million from a prior-year loss highlights enhanced operational efficiency and a favorable sales mix, which led to a gross margin expansion to 72%. This margin improvement, coupled with disciplined operating expense management, demonstrates the company's ability to scale profitably.

Regarding liquidity and capital resources, management highlights the robust operating cash flow of $30 million and healthy cash and equivalents balance of $65 million. This strong cash position, combined with minimal long-term debt, provides substantial financial flexibility. These resources, management believes, sufficiently fund ongoing operations, planned capital expenditures, and strategic investments, including the ambitious R&D initiatives and practitioner network expansion outlined in the future outlook. The company's conservative debt profile further strengthens its financial health and capacity for future growth. Management continuously monitors key performance indicators and market trends to adapt its strategies and maintain financial stability.

5. Financial Health

biote Corp. demonstrates strong financial health. The company generated $30 million in operating cash flow in 2025, reflecting its ability to convert sales into cash effectively. Ending the year with a robust cash and equivalents balance of $65 million, a significant increase from the prior year, provides ample liquidity. Its balance sheet shows total assets of $210 million and a very manageable long-term debt of $10 million, reflecting a low leverage ratio. This strong liquidity and low debt burden position the company favorably to fund its growth initiatives, manage potential economic fluctuations, and pursue strategic opportunities without significant financial strain.

6. Future Outlook

biote Corp.'s strategy for 2026 and beyond centers on three key pillars:

1. Practitioner Network Expansion: The company plans to grow its certified practitioner base by an additional 15-20% in 2026, particularly targeting underserved geographic regions to broaden market access.
2. Product Innovation: Significant investment in R&D (approximately 10% of revenue) will fund the development of new hormone-related therapies and the expansion of its supplement line, with two new product launches anticipated in late 2026, to enhance its product portfolio and address evolving patient needs.
3. Patient Engagement & Education: Enhanced digital marketing and educational initiatives will increase patient awareness and drive demand for its personalized wellness solutions, fostering deeper connections with end-users.

Management projects continued revenue growth of 20-25% for 2026, as it anticipates sustained demand for its services and products and successful execution of its strategic initiatives.

7. Competitive Position

biote Corp. operates in a competitive yet growing market for hormone optimization and wellness solutions. The company's competitive advantages stem primarily from its proprietary method of hormone pellet insertion, supported by extensive practitioner training and certification. This specialized network of certified practitioners creates a significant barrier to entry and fosters strong brand loyalty. Furthermore, biote's established brand reputation within the hormone optimization space, built on a foundation of education and practitioner support, differentiates it from general wellness companies. The integrated offering of both hormone therapy and a complementary line of dietary supplements provides a holistic solution that enhances patient outcomes and strengthens its market position. While the market includes both large pharmaceutical companies and smaller, specialized wellness brands, biote's focus on a comprehensive, practitioner-led model and its commitment to innovation in personalized wellness solutions enable it to maintain a distinct and defensible competitive stance.

Overall Assessment:

biote Corp.'s 2025 performance demonstrates strong financial health and effective execution of its growth strategy. The company successfully expands its market reach and improves profitability. While the "Emerging Growth Company" status provides flexibility, investors should carefully weigh the growth potential against the inherent risks associated with regulatory environments, competition, and the reliance on its practitioner network. Its strong cash position and low debt provide a solid foundation for future expansion.